Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
| ▸ | CCNC | P24863 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 13/20 | 0.36 |
| ▸ | FLT3 | P36888 | 3/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26792311 | 0.92 | CCNC (0.34) | CCNCCDK8IRAK4 | |
| SCHEMBL29315570 | 0.90 | IRAK4 (0.40) | CCNCCDK8IRAK4 | |
| SCHEMBL29329331 | 0.87 | KDM1A (0.35) | SMN1; SMN2AURKBJAK2 | |
| SCHEMBL29315543 | 0.86 | GRIN2B (0.34) | CCNCCDK8IRAK4 | |
| SCHEMBL29315539 | 0.86 | GRIN2B (0.36) | — | |
| SCHEMBL29315527 | 0.86 | NR1I2 (0.33) | SMN1; SMN2CCNCCDK8JAK2L3MBTL1 | |
| SCHEMBL23037607 | 0.85 | FLT3 (0.40) | FLT3JAK2 | |
| SCHEMBL30539803 | 0.85 | FLT3 (0.40) | FLT3JAK2 | |
| SCHEMBL29315545 | 0.85 | GRIN2B (0.36) | CCNCCDK8JAK2 | |
| SCHEMBL26788255 | 0.85 | KDM4E (0.37) | SMN1; SMN2CCNCCDK8JAK2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | SMN1; SMN2 4781/4885AURKA 1967/4885AURKB 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.